Possible heart failure exacerbation associated with rosiglitazone: Case report and literature review

Pharmacotherapy

Volumn 23, Issue 7, 2003, Pages 945-954

  Page II, Robert Lee ^a   Gozansky, Wendolyn S ^a   Ruscin, J Mark ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; DIURETIC AGENT; GLIBENCLAMIDE; ROSIGLITAZONE;

AGED; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DISEASE EXACERBATION; DRUG WITHDRAWAL; DYSPNEA; EDEMA; GLUCOSE INTOLERANCE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; INSULIN RESISTANCE; JUGULAR VEIN; LUNG EDEMA; MALE; MEDICAL LITERATURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT COMPLIANCE; SIDE EFFECT; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; VEIN DILATATION; WEIGHT GAIN;

AGED; DIABETES MELLITUS, TYPE 2; HEART FAILURE, CONGESTIVE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; THIAZOLIDINEDIONES;

EID: 0038381739     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.7.945.32721     Document Type: Article

References (63)

1. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications: estimates and projections to the year 2010. Diabet Med 1997;14(suppl 5):S1-85.
2. Campbell IW. Epidemiology and clinical presentation of type 2 diabetes. Value Health 2000;3(suppl 1):S3-6.
3. Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incidence of cardiovascular events: a meta-regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999;22(2):233-40.
4. Cohn JN, Archibald DG, Ziesche S, et al. Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration cooperative study. N Engl J Med 1986;314:1547-52.
5. American Heart Association. 2002 heart and stroke statistical update. Dallas, TX: American Heart Association, 2002.
6. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241(14):2035-8.
7. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34(1):29-34.
8. Chae CU, Glynn RJ, Anson JE, Guralnik M, Taylor JO, Pfeffer MA. Diabetes predicts congestive heart failure risk in the elderly [abstr]. Circulation 1998;98(suppl 1):658.
9. Amato L, Paolisso G, Cacciatore F, et al. Congestive heart failure predicts the development of non-insulin dependent diabetes in the elderly. Diabetes Metab 1997;23(3):213-18.
10. Swan JW, Anker SD, Walton C, et al. Insulin resistance in chronic heart failure: relation to severity and etiology of heart failure. Eur Heart J 1994;15:1528-32.
11. Swan JW, Walton C, Godsland IF, Clark AL, Coats AJ, Oliver M. Insulin resistance in chronic heart failure. J Am Coll Cardiol 1997;30(2):527-32.
12. Suskin N, McKelvie RS, Burns RJ, et al. Glucose and insulin abnormalities relate to functional capacity in patients with heart failure. Eur Heart J 2000;21(16):1368-75.
13. Shindler DM, Kostis JB, Yusuf S, et al. Diabetes mellitus, a predictor of morbidity and mortality in the studies of left ventricular dysfunction (SOLVD) trials and registry. Am J Cardiol 1996;77 (11):1017-20.
14. Melchior T, Rask-Madsen C, Torp-Pedersen C, Hildebrandt P, Kober L, Jensen G. The impact of heart failure on prognosis of diabetic and non-diabetic patients with myocardial infarction: a 15 year follow-up study. Eur J Heart Fail 2001;3(1):83-90.
15. Dries DL, Sweitzer NK, Drazner MH, Stevenson LW, Gersh BJ. Prognostic impact of diabetes mellitus in patients with heart failure according to the etiology of left ventricular systolic dysfunction. J Am Coll Cardiol 2001;38(2):421-8.
16. Bristol Myers Squibb. Metformin (Glucophage) package insert. Princeton, NJ; May 2001.
17. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA. Lactic acidosis in patients with diabetes treated with metformin [letter]. N Engl J Med 1998;338(4):265-6.
18. Glaxo SmithKline. Rosiglitazone (Avandia) package insert. Philadelphia, PA; February 2001.
19. American College of Cardiology/American Heart Association. Guidelines for the evaluation and management of chronic heart failure in the adult. Available from http://www.acc.org/clinical/guidelines/failure/hf_index.htm. Accessed June 4, 2002.
20. Food and Drug Administration. Summary letter. Available from http://www.fda.gov/medwatch/SAFETY/2002/summary-actos-avandia. PDE Accessed June 4, 2002.
21. Hirsch IB, Kelly J, Cooper S. Pulmonary edema associated with troglitazone therapy [letter]. Arch Intern Med 1999;159:1811.
22. Gorson DM. Significant weight gain with Rezulin therapy [letter]. Arch Intern Med 1999;159:99.
23. Thomas ML, Lloyd SJ. Pulmonary edema associated with rosiglitazone and troglitazone [letter]. Ann Pharmcother 2001;35:123-4.
24. Niemeyer NV, Janney LM. Thiazolidinedione-induced edema. Pharmacotherapy 2002;22:924-9.
25. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997;336:525-33.
26. Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: a randomized trial - the losartan heart failure survival study ELITE II. Lancet 2000;355:1582-7.
27. CONCENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med 1987;316:1429-35.
28. SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992;327:685-91.
29. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991;325:293-302.
30. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1992;327:669-77.
31. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991;325:303-10.
32. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24(9):1614-19.
33. Tang WH, Young JB. Cardiomyopathy and heart failure in diabetes. Endocrinol Metab Clin North Am 2001;30(4):1031-46.
34. Marangou AG, Alford FP, Ward G, et al. Hormonal effects of norepinephrine on acute glucose disposal in humans: a minimal model analysis. Metabolism 1988;37(9):885-91.
35. Paolisso G, Tagliamonte MR, Rizzo MR, et al. Prognostic importance of insulin-mediated glucose uptake in aged patients with congestive heart failure secondary to mitral and/or aortic valve disease. Am J Cardiol 1999;83(9):1338-44.
36. Paolisso G, De Riu S, Marrazzo G, Verza M, Varricchio M, D'Ondofrio F. Insulin resistance and hyperinsulinemia in patients with chronic congestive heart failure. Metabolism 1991;40(9):972-7.
37. Feldman AM, Combes A, Wagner D, et al. The role of tumor necrosis factor in the pathophysiology of heart failure. J Am Coll Cardiol 2000;35(3):537-44.
38. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends Endocrinol Metabol 2000;11(6):212-17.
39. Mishima Y, Kuyama A, Tada A, Takahashi K, Ishioka T, Kibata M. Relationship between serum tumor necrosis factor alpha and insulin resistance in obese men with type 2 diabetes mellitus. Diabetes Res Clin Pract 2001;52(2):119-23.
40. Taegtmeyer H, McNulty P, Young M. Adaptation and maladaptation of the heart in diabetes, part 1. General concepts. Circulation 2002;105:1727-33.
41. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
42. Solang L, Malmberg K, Ryden L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999;20:789-95.
43. Bell DS. Diabetic cardiomyopathy: a unique entity or a complication of coronary artery disease? Diabetes Care 1995;18:708-14.
44. Bonow RO, Mitch WE, Nesto RW, et al. Prevention conference VI diabetes and cardiovascular disease writing group: management of cardiovascular-renal complications. Circulation 2002;105:1-6.
45. UK Prospective Diabetes Study (UKPDS) Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.
46. Horlen C, Malone R, Bryant B, et al. Frequency of inappropriate metformin prescriptions [letter]. JAMA 2002;287(19):2504-5.
47. Emslie-Smith AM, Boyle DI, Evans JM, Sullivan F, Morris AD. Contraindications to metformin therapy in patients with type 2 diabetes - a population-based study of adherence to prescribing guidelines. Diabet Med 2001;18(6):483-8.
48. McTernan PG, Harte AL, Anderson LA, et al. Insulin and rosiglitazone regulation of lipolysis and lipogenesis in human adipose tissue in vitro. Diabetes 2002;51(5):1493-8.
49. Marx N, Kehrle B, Kohlhammer K, et al. PPAR activators as anti-inflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis. Circ Res 2002;90(6):703-10.
50. Goetze S, Xi XP, Kawano Y, et al. TNF-alpha induced migration of vascular smooth muscle cells is MAPK dependent. Hypertension 1999;33(1 pt 2):183-9.
51. Iwata M, Haruta T, Usui I, et al. Pioglitazone ameliorates tumor necrosis factor alpha induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome prolife rator-activated receptor gamma. Diabetes 2001;50:1083-92.
52. Mykkanen L. Prevention of coronary heart disease in type 2 diabetes. Int J Clin Pract 2000;suppl (113):40-5.
53. Takeda Pharmaceuticals America, Inc. Pioglitazone, Actos package insert. Lincolnshire, IL; January 2002.
54. Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients. Diabetes Care 1999;22(6):908-11.
55. Kaplan F, Al-Majali K, Betteride, DJ. PPARS, insulin resistance and type 2 diabetes. J Cardiovasc Risk 2001;8:211-17.
56. Yoshioka S, Nishino H, Shiraki T, et al. Anithypertensive effects of CS-045 treatment in obese Zucker rats. Metabolism 1993;42(1):75-80.
57. Kaufman LN, Peterson MM, DeGrange LM. Pioglitazone attenuates diet-induced hypertension in rats. Metabolism 1995;44(9):1105-9.
58. Buchanan TA, Meehan WP, Jeng YY, et al. Blood pressure lowering by pioglitazone: evidence for a direct vascular effect. J Clin Invest 1995;96(1):354-60.
59. Walker AB, Naderali EK, Chattington PD, Buckingham RE, Williams G. Differential vasoactive effects of the insulin sensitizers rosiglitazone (BRL 49653) and troglitazone on human small arteries in vitro. Diabetes 1998;47:810-14.
60. Anonymous. FDA drug recalls and withdrawals. Saftey-based withdrawals in 2000. Available from www.fda.gov/cder/reports/RTN2000/RTN2000-3.HTM. Accessed January 1, 2003.
61. Inoue K, Sano H. Troglitazone-induced pulmonary edema [letter]. Arch Intern Med 2000;160:871-2.
62. Kelly J, Hirsch I, Cooper S. Troglitazone-induced pulmonary edema [reply]. Arch Intern Med 2000;160:871-2.
63. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.